Evolution of the Average Target: Replimune Group, Inc.

Evolution of the Target Price: Replimune Group, Inc.

Changes in Analyst Recommendations: Replimune Group, Inc.

6a8a.o54poUk4Y-78dJRYyk5YYw5DZ693qnpwTDcs1071Q6Q.yNtsyAFQB4qkGc0tvAAAKXc7JthawD8DO3NJsTykKcrW3EzIPBVTuoka1Q~2f923d423b5a6600a92212ca3dd2b69c
08-07 Wedbush Upgrades Replimune Group to Outperform From Neutral, Adjusts PT to $19 From $12 MT
08-04 Leerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11 MT
07-31 Top Midday Gainers MT
07-31 Cantor Fitzgerald Upgrades Replimune to Overweight From Neutral MT
07-31 Wedbush Upgrades Replimune Group to Outperform From Neutral, Raises Price Target to $12 From $9 MT
06-30 BMO Capital Upgrades Replimune to Outperform From Underperform, Adjusts PT to $16 From $1 MT
06-29 Wedbush Lifts Price Target on Replimune to $9 From $6, Maintains Neutral Rating MT
06-26 JPMorgan Upgrades Replimune Group to Overweight From Neutral, $17 Price Target MT
05-29 Wedbush Adjusts Price Target on Replimune Group to $6 From $2, Maintains Neutral Rating MT
04-13 Top Midday Decliners MT
04-13 Replimune Group Facing 'Significant Risk' on RP1's Ongoing Phase 3 Study, Wedbush Says MT
04-13 Top Premarket Decliners MT
04-13 Piper Sandler Downgrades Replimune to Neutral From Overweight, Adjusts Price Target to $4 From $14 MT
04-13 Cantor Fitzgerald Downgrades Replimune Group to Neutral From Overweight MT
04-13 BMO Capital Downgrades Replimune to Underperform From Market Perform, Adjusts PT to $1 From $11 MT
04-13 JPMorgan Downgrades Replimune Group to Underweight From Neutral, $10 Price Target MT
04-13 Leerink Partners Downgrades Replimune Group to Market Perform From Outperform, Adjusts Price Target MT
04-13 HC Wainwright Downgrades Replimune to Sell From Buy MT
04-13 Wedbush Downgrades Replimune Group to Neutral From Outperform, Cuts Price Target to $2 From $19 MT
02-04 Wedbush Raises Price Target on Replimune Group to $19 From $18, Keeps Outperform Rating MT
11-03 BMO Capital Upgrades Replimune Group to Market Perform From Underperform, Adjusts Price Target to $11 From $2 MT
25-10-27 Replimune Group Rise After HC Wainwright Upgrade MT
25-10-27 HC Wainwright Upgrades Replimune Group to Buy From Neutral, Price Target is $12 MT
25-10-21 Piper Sandler Upgrades Replimune Group to Overweight From Neutral, Adjusts Price Target to $13 From $8 MT
25-10-20 JPMorgan Upgrades Replimune Group to Neutral From Underweight, $11 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+50.46%
+27.82%
+3.39%
+28.22%
+24.34%
+51.37%
-5.61%
+26.23%
-3.29%
+6.68%
Average +20.96%
Weighted average by Cap. +21.08%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.87USD
Average target price
19.50USD
Spread / Average Target
+51.52%
High Price Target
24.00USD
Spread / Highest target
+86.48%
Low Price Target
14.00USD
Spread / Lowest Target
+8.78%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. REPL Stock
  4. Consensus Replimune Group, Inc.
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!